Metabolic dysfunction–Associated Steatotic Liver Disease
Conditions
Interventions
Adult patients undergoing assessment for cardiovascular metabolic diseases:None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age >=18 years and <80 years. 2.Suspected coronary artery disease, with completed coronary angiography or CTA examination. 3.Completed non-invasive FibroScan assessment, with available liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) values for baseline and follow-up analysis.
Exclusion criteria
Exclusion criteria: 1.Patients with other definite liver diseases at baseline or during follow-up, including those positive for hepatitis B surface antigen, untreated active hepatitis C virus infection, drug-induced liver injury, autoimmune liver disease, and hereditary liver diseases. 2.Patients with active viral infections, such as HIV infection or other active infections that may affect liver function and metabolism, to avoid confounding effects on the analysis. 3.Patients with a history of malignancy at baseline or within the past five years, to prevent interference from tumors and related treatments on liver and cardiovascular status. 4.Pregnant or breastfeeding women, to avoid physiological influences on liver fat metabolism and fluid status. 5.Patients with incomplete key assessments or missing critical follow-up data, such as missing FibroScan, imaging, or laboratory measurements, to ensure the integrity of primary outcome measures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Follow-up content: Dynamic monitoring of FibroScan results (liver stiffness and CAP value), liver-related events (LRE), major adverse cardiovascular events (MACE), control of blood pressure, blood glucose, and lipids, medication adjustments, and occurrences of liver and kidney function abnormalities and adverse events.;Baseline characteristics, including: 1. Demographic features (age, sex, BMI, lifestyle factors, and family history); 2. Cardiovascular and metabolic risk factors (blood pressure, blood glucose, lipids, HDL-C, and history of prior cardiovascular events); 3. Liver-related parameters (ALT, AST, FibroScan LSM and CAP values, imaging-based assessment of hepatic fat); 4. Laboratory parameters (complete blood count, liver and kidney function, inflammatory and metabolic biomarkers); 5. Medicat; | — |
Secondary
| Measure | Time frame |
|---|---|
| Demographic information: age, sex, height, weight, body mass index (BMI), lifestyle, and family history.; | — |
Countries
China
Contacts
Public ContactZheng Minghua
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed